
Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

CAR-T CELL THERAPY CAUSES INFLAMMATION BY IL-1 WHICH ACTIVATES INFLAMMATORY CYTOKINE MAST CELLS: ANTI-INFLAMMATORY ROLE OF IL-37
Vol 33, Issue 6, 2019
Abstract
Chimeric antigen receptor (CAR) T cells are genetically modified T cells that act against cancer. When CAR-T cells are administered they can trigger inflammatory cytokines and increase toxicity. Interleukin (IL)-1 is the classic cytokine that mediates inflammatory reactions including those that occur in CAR-T-cell therapy. IL-1 also induces IL-33 in mast cells (MCs), amplifying the allergic reaction. IL- 37 (ILF7) is an IL-1 family member which binds IL-18 receptor alpha (IL-18Rα) chain and suppresses innate and acquired immunity. IL-37 is an anti-inflammatory cytokine which inhibits pro-inflammatory cytokines including IL-1 and IL-33. Here, we hypothesize that inflammation and toxicity generated in tumor CAR-T therapy could be inhibited by IL-37, contributing to an improvement in the treatment of tumors with CAR-T therapy.
Keywords
References
Supporting Agencies
Copyright (c) 2019 Al. Caraffa, C.E. Gallenga, S.K. Kritas, G. Ronconi, P.Di Emidio, P. Conti
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Medical Genetics, University of Torino Medical School, Italy

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy